Roche moves to acquire PathAI for up to $1.05 billion in major AI pathology push
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business.
Subscribe To Our Newsletter & Stay Updated